Platelet reactivity and hemorrhage risk in neurointerventional procedures under dual antiplatelet therapy

被引：27

作者：

Nishi, Hidehisa ^{[1
]}

Nakahara, Ichiro ^{[2
]}

Matsumoto, Shoji ^{[1
,3
]}

Hashimoto, Tetsuya ^{[4
]}

Ohta, Tsuyoshi ^{[5
]}

Sadamasa, Nobutake ^{[1
]}

Ishibashi, Ryota ^{[1
]}

Gomi, Masanori ^{[1
]}

Saka, Makoto ^{[1
]}

Miyata, Haruka ^{[1
]}

Watanabe, Sadayoshi ^{[2
]}

Okata, Takuya ^{[1
]}

Sonoda, Kazutaka ^{[1
]}

Kouge, Junpei ^{[1
]}

Ishii, Akira ^{[1
]}

Nagata, Izumi ^{[1
]}

Kira, Jun-ichi ^{[3
]}

机构：

[1] Kokura Mem Hosp, Dept Neurosurg, Fukuoka, Japan

[2] Fujita Hlth Univ, Dept Neurosurg, Toyoake, Aichi, Japan

[3] Kyushu Univ, Grad Sch Med Sci, Neurol Inst, Dept Neurol, Fukuoka, Japan

[4] Natl Cerebral & Cardiovasc Ctr, Dept Cerebrovasc Med, Osaka, Japan

[5] Kochi Hlth Sci Ctr, Dept Neurosurg, Kochi, Japan

来源：

JOURNAL OF NEUROINTERVENTIONAL SURGERY | 2016年 / 8卷 / 09期

关键词：

Drug; Hemorrhage; Intervention; Pharmacology;

D O I：

10.1136/neurintsurg-2015-011844

中图分类号：

R445 [影像诊断学];

学科分类号：

100207 ;

摘要：

Background and purpose Hemorrhagic complications during neurointerventional procedures have various etiologies and can result in severe morbidity and mortality. This study investigated the possible association between low platelet reactivity measured by the VerifyNow assay and increased hemorrhagic complications during elective neurointervention under dual antiplatelet therapy. Methods From May 2010 to April 2013 we recorded baseline characteristics, P2Y12 reaction units (PRU), and aspirin reaction units using VerifyNow. The primary endpoint was post-procedural hemorrhagic complications. Results A total of 279 patients were enrolled and 31 major hemorrhagic complications (11.1%) were identified. From receiver-operating characteristic curve analysis, PRU values could discriminate between patients with and without major hemorrhagic complications (area under the curve 0.63). Aspirin reaction unit values had no association with the primary outcome. The optimal cut-off for the primary outcome (PRU <= 175) was used to identify the low platelet reactivity group. The incidence of hemorrhagic complications was 20.0% in this group and 8.9% in the non-low platelet reactivity group. Multivariate analysis identified low platelet reactivity as an independent predictor for hemorrhagic complications. Conclusions The risk of hemorrhagic complications during elective neurointervention including cerebral aneurysm coil embolization and carotid artery stenting under dual antiplatelet therapy is associated with the response to clopidogrel but not to aspirin. A PRU value of <= 175 discriminates between patients with and without hemorrhagic complications. Future prospective studies are required to validate whether a specific PRU value around 170-180 is predictive of hemorrhagic complications.

引用

页码：949 / 953

页数：5

共 23 条

[11] Delgado Almandoz J.E., Crandall B.M., Scholz J.M., Et al., Pre-procedure p2-12 reaction units value predicts perioperative thromboembolic and hemorrhagic complications in patients with cerebral aneurysms treated with the pipeline embolization device, J Neurointerv Surg, 5, pp. iii3-10, (2013)
[12] Delgado Almandoz J.E., Crandall B.M., Scholz J.M., Et al., Last-recorded P2-12 reaction units value is strongly associated with thromboembolic and hemorrhagic complications occurring up to 6 months after treatment in patients with cerebral aneurysms treated with the Pipeline Embolization Device, AJNR Am J Neuroradiol, 35, pp. 128-135, (2014)
[13] Schulman S., Angeras U., Bergqvist D., Et al., Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients scientific and standardization committee communication, J Thromb Haemost, 3, pp. 692-694, (2005)
[14] Delgado Almandoz J.E., Kadkhodayan Y., Crandall B.M., Et al., Variability in initial response to standard clopidogrel therapy, delayed conversion to clopidogrel hyper-response and associated thromboembolic and hemorrhagic complications in patients undergoing endovascular treatment of unruptured cerebral aneurysms, J Neurointerv Surg, 6, pp. 767-773, (2014)
[15] Cura F.A., Kapadia S.R., L'Allier P.L., Et al., Safety of femoral closure devices after percutaneous coronary interventions in the era of glycoprotein IIb/IIIa platelet blockade, Am J Cardiol, 86, pp. 780-782, (2006)
[16] Ellis S.G., Elliot J., Horrigan M., Et al., Low-normal or excessive body mass index: Newly identified and powerful risk factors for death and other complications with percutaneous coronary intervention, Am J Cardiol, 78, pp. 642-646, (1996)
[17] Hitinder S.G., Whitlow P.L., Kip K.E., The impact of body mass index on short-And long-Term outcomes in patients undergoing coronary revascularization, J Am Coll Cardiol, 39, pp. 834-840, (2002)
[18] Hitinder S.G., Brennan D.M., Booth J., Et al., Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox, Am J Cardiol, 90, pp. 42-45, (2002)
[19] Mandak J.S., Blankenship J.C., Gardner L.H., Et al., Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide, J Am Coll Cardiol, 31, pp. 1518-1524, (1998)
[20] Blankenship J.C., Hellkamp A.S., Aguirre F.V., Et al., Vascular access site complications after percutaneous coronary interventions with abciximab in the evaluation of c7e3 for the prevention of ischemic complications (epic) trial, Am J Cardiol, 81, pp. 36-40, (1998)

← 1 2 3 →